I believe that allocating $24 billion to develop prototype vaccines for every known viral family is an inefficient use of resources. This approach spreads our efforts too thin and assumes that all viruses pose an equal threat, which isn't the case. We should prioritize funding for targeted vaccine research and development based on the severity and probability of viral outbreaks, as well as invest in broad-spectrum antiviral treatments and better healthcare infrastructure.